David Allan

SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ

SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ

YM Biosciences USA, Inc. develops and commercializes pharmaceutical products. The company was founded on November 23, 2005 and is headquartered in Wayne, PA.

Orion Securities, Inc. is an independent broker/dealer headquartered in Toronto with additional offices in Calgary and Montréal and Chicago. The firm provides research, trade execution, underwriting and advisory services. Orion's research team focuses on mining, energy, healthcare, biotechnology, technology and diversified industries. They focus primarily on Canadian-based stocks

SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ

SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ

SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ

SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ

Orion Securities, Inc. is an independent broker/dealer headquartered in Toronto with additional offices in Calgary and Montréal and Chicago. The firm provides research, trade execution, underwriting and advisory services. Orion's research team focuses on mining, energy, healthcare, biotechnology, technology and diversified industries. They focus primarily on Canadian-based stocks

SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ

Orion Securities, Inc. is an independent broker/dealer headquartered in Toronto with additional offices in Calgary and Montréal and Chicago. The firm provides research, trade execution, underwriting and advisory services. Orion's research team focuses on mining, energy, healthcare, biotechnology, technology and diversified industries. They focus primarily on Canadian-based stocks

SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ

Orion Securities, Inc. is an independent broker/dealer headquartered in Toronto with additional offices in Calgary and Montréal and Chicago. The firm provides research, trade execution, underwriting and advisory services. Orion's research team focuses on mining, energy, healthcare, biotechnology, technology and diversified industries. They focus primarily on Canadian-based stocks

Orion Securities, Inc. is an independent broker/dealer headquartered in Toronto with additional offices in Calgary and Montréal and Chicago. The firm provides research, trade execution, underwriting and advisory services. Orion's research team focuses on mining, energy, healthcare, biotechnology, technology and diversified industries. They focus primarily on Canadian-based stocks

Orion Securities, Inc. is an independent broker/dealer headquartered in Toronto with additional offices in Calgary and Montréal and Chicago. The firm provides research, trade execution, underwriting and advisory services. Orion's research team focuses on mining, energy, healthcare, biotechnology, technology and diversified industries. They focus primarily on Canadian-based stocks

Loewen, Ondaatje, McCutcheon Ltd. (LOM) is an independent Canadian broker/dealer firm headquartered in Toronto, Ontario. Founded in 1970, the firm combines objective research and value-added financing ideas with institutional sales, trading and investment banking. They are a provider of value-added North American research. LOM focuses exclusively on advising small and mid-cap companies, with a strong focus on select emerging growth companies in industries that include Technology, Healthcare, and Mining.

SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ

SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ

Orion Securities, Inc. is an independent broker/dealer headquartered in Toronto with additional offices in Calgary and Montréal and Chicago. The firm provides research, trade execution, underwriting and advisory services. Orion's research team focuses on mining, energy, healthcare, biotechnology, technology and diversified industries. They focus primarily on Canadian-based stocks

Orion Securities, Inc. is an independent broker/dealer headquartered in Toronto with additional offices in Calgary and Montréal and Chicago. The firm provides research, trade execution, underwriting and advisory services. Orion's research team focuses on mining, energy, healthcare, biotechnology, technology and diversified industries. They focus primarily on Canadian-based stocks

Orion Securities, Inc. is an independent broker/dealer headquartered in Toronto with additional offices in Calgary and Montréal and Chicago. The firm provides research, trade execution, underwriting and advisory services. Orion's research team focuses on mining, energy, healthcare, biotechnology, technology and diversified industries. They focus primarily on Canadian-based stocks

Orion Securities, Inc. is an independent broker/dealer headquartered in Toronto with additional offices in Calgary and Montréal and Chicago. The firm provides research, trade execution, underwriting and advisory services. Orion's research team focuses on mining, energy, healthcare, biotechnology, technology and diversified industries. They focus primarily on Canadian-based stocks